Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 17/10/2017
SIETES contiene 92076 citas

 
 
 1 a 20 de 2176 siguiente >>
Presentar resultados
Seleccionar todas
1. Cita con resumen
Ekelboom JW, Connolly SJ, Bosch J, Dagenais GR, Hart RG, Shestakovska O, Díaz R, Alings M, Lonn EM, Anand SS, Widimsky P, Hori M, Avezum A, Piegas LS, Branch KRH, Probstfield J, Bhatt DL, Zhu J, Liang Y, Maggioni AP, Lopez-Jaramillo P, O'Donnell M, Kakkar AK, Fox KAA, Parkhomenko AN, Ertl G, Störk S, Keltai M, Ryden L, Pogosova N, Dans AL, Lanas F, Commerford PJ, Torp-Pedersen C, Guzik TJ, Verhamme PB, Vinereanu D, Kim J-H, Tonkin AM, Lewis BS, Felix C, Yusoff K, Steg PG, Metsarinne KP, Bruns NC, Misselwitz F, Chen E, Leong D, Yusuf S, for the COMPASS Investigators. Rivaroxaban with or without aspirin in stable cardiovascular disease. N Engl J Med 2017:5 de octubre. [Ref.ID 102087]
2.Tiene citas relacionadas Cita con resumen
Gieling EM, van den Ham HA, van Onzenoort H, Bos J, Kramers C, de Boer A, de Vries F, Burden AM. Risk of major bleeding and stroke associated with the use of vitamin K antagonists, nonvitamin K antagonist oral anticoagulants and aspirin in patients with atrial fibrillation: a cohort study. Br J Clin Pharmacol 2017;83:1844-59. [Ref.ID 102014]
3. Cita con resumen
Rojas-Velandia C, Ruiz-Garzón J, Moscoso-Alcina J-C, Vallejos-Narváez A, Castro-Canoa J, Bustos-Martínez Y, Flórez-Cutiva M, Contreras-Muñoz M, Gómez-Gil JC, Calderón-Ospina C-A. Characterization of adverse drug reactions causing admission to an intensive care unit. Br J Clin Pharmacol 2017;83:1134-40. [Ref.ID 101974]
4.Enlace a cita original Cita con resumen
Wändell P, Carlsson AX, Holzmann M, Ärnlöv J, Johansson SE, Sundquist J, Sundquist K. Association between antithrombotic treatment and hemorrhagic stroke in patients with atrial fibrillation - A cohort study in primary care. Eur J Clin Pharmacol 2017;73:febrero. [Ref.ID 101404]
5.Tiene citas relacionadas
Jolly SS, Natarajan MK. Atrial fibrillation and PCI - Do we still need aspirin?. N Engl J Med 2016;373:2490-2. [Ref.ID 101034]
6.Tiene citas relacionadas Cita con resumen
Gibson CM, Mehran R, Bode C, Halperin J, Verheugt FW, Wildgoose P, Birmingham M, Ianus J, Burton P, van Eickels M, Korjian S, Daaboul Y, Lip GYH, Cohen M, Husted S, Peterson ED, Fox KA. Prevention of bleeding in patients with atrial fibrillation undergoing PCI. N Engl J Med 2016;373:2423-34. [Ref.ID 101032]
7. Cita con resumen
Nielen JTH, Dagnelie PC, Emans PJ, Veldhorst-Janssen N, Lalmohamed A, Van Staa T-P, Boonen AERCH, van den Bemt BJF, de Vries F. Safety and efficacy of new oral anticoagulants and low-molecular-weight heparins compared with aspirin in patients undergoing total knee and hip replacements. Pharmacoepidemiol Drug Saf 2016;25:1245-52. [Ref.ID 100896]
8. Cita con resumen
Gargiulo G, Windecker S, da Costa BR, Feres F, Hong M-K, Gilard M, Kim H-S, Colombo A, Bhatt DL, Kim B-K, Morice M-C, Park KW, Chieffo A, Palmerini T, Stone GW, Valgimigli M. Short term versus long term dual antiplatelet therapy after implantation of drug eluting stent in patients with or without diabetes: systematic review and meta-analysis of individual participant data from randomised trials. BMJ 2016;355:i5483. [Ref.ID 100878]
9. Cita con resumen
Anónimo. FDA approves drug designed to protect heart patients from aspirin-related stomach ulcers. Drugs.com 2016:16 de septiembre. [Ref.ID 100669]
10.Enlace a cita originalTiene citas relacionadas
Hankey GJ. The benefits of aspirin in early secondary stroke prevention. N Engl J Med 2016;388:312-4. [Ref.ID 100643]
11. Cita con resumen
Johnston SC, Amarenco P, Albers GW, Denison H, Easton D, Evans SR, Held P, Jonasson J, Minematsu K, Molina CA, Wang Y, Wong KSL, for the SOCRATES Steering Committee and Investigators. Ticagrelor versus aspirin in acute stroke or transient ischemic attack. N Engl J Med 2016;375:35-43. [Ref.ID 100628]
12. Cita con resumen
Chan FK, Leung KE, Wong GL, Ching JY, Tse YK, Au KW, Wu JC, Nq SC. Risks of bleeding recurrence and cardiovascular events with continued aspirin use after lower gastrointestinal hemorrhage. Gastroenterology 2016;151:271-7. [Ref.ID 100594]
13. Cita con resumen
Wang Y, Zhao X, Lin J, Johnston C, Lin Y, Pan Y, Liu L, Wang D, Wang C, Meng X, Xu J, for the CHANCE Investigators. Association between CYP2C19 loss-of-function allele status and efficacy of clopidogrel for risk reduction among patients with minor stroke or transient ischemic attack. JAMA 2016;316:70-8. [Ref.ID 100516]
14. Cita con resumen
Baharoglu M, Cordonnier C, Salman RAS, de Gans K, Koopman MM, Brand A, Majoie CB, Beenen LF, Marquering HA, Vermeulen M, Nederkoorn PJ, de Haan RJ, Roos YB, PATCH Investigators. Platelet transfusion versus standard care after acute stroke due to spontaneous cerebral haemorrhage associated with antiplatelet therapy (PATCH): a randomised, open-label, phase 3 trial. Lancet 2016;387:2605-13. [Ref.ID 100468]
15.Enlace a cita originalTiene citas relacionadas
Baigent C. Aspirin for disease prevention: public policy or personal choice?. Ann Intern Med 2016;164:846-7. [Ref.ID 100467]
16.Enlace a cita originalTiene citas relacionadas
Bibbins-Domingo K, on behalf of the U.S. Preventive Task Force. Aspirin use for the primary prevention of cardiovascular disease and colorectal cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2016;164:836-45. [Ref.ID 100466]
17.Enlace a cita originalTiene citas relacionadas
Whitlock EP, Burda BU, Williams SB, Guirguis-Blake JM, Evans CV. Bleeding risks with aspirin use for primary prevention in adults: a systematic review for the U.S. Preventive Services Task Force. Ann Intern Med 2016;164:826-35. [Ref.ID 100465]
18.Enlace a cita originalTiene citas relacionadas
Chubak J, Whitlock EP, Williams SB, Kamineni A, Burda BU, Buist DSM, Anderson ML. Aspirin for the prevention of cancer incidence and mortality: systematic evidence reviews for the U.S. Preventive Services Task Force. Ann Intern Med 2016;164:814-25. [Ref.ID 100464]
19.Enlace a cita originalTiene citas relacionadas
Guirguis-Blake JM, Evans CV, Senger CA, O'Connor EA, Whitlock EP. Aspirin for the primary prevention of cardiovascular events: a systematic evidence review for the U.S. Preventive Services Task Force. Ann Intern Med 2016;164:804-13. [Ref.ID 100463]
20.Enlace a cita originalTiene citas relacionadas Cita con resumen
Dehmer SP, Maciosek MV, Flottemesch TJ, LaFrance AB, Whitlock EP. Aspirin for the primary prevention of cardiovascular disease and colorectal cancer: a decision analysis for the U.S. Preventive Services Task Force. Ann Intern Med 2016;164:777-86. [Ref.ID 100462]
Seleccionar todas
 
 1 a 20 de 2176 siguiente >>